Brief: Biocartis: New Idylla EGFR Study Shows Reduction Of Time-To-Treatment For Lung Cancer Patients

Biocartis NV

08/11/2022 06:09

Nov 8 (Reuters) - Biocartis Group NV  BCART.BR :
    * NEW IDYLLA™ EGFR STUDY SHOWS REDUCTION OF
TIME-TO-TREATMENT BY
48% FOR LUNG CANCER PATIENTS

Source text for Eikon:  ID:nGNE8Qcz10 
Further company coverage:  BCART.BR 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))